Determination of basic Fibroblast Growth Factor levels in serum of tumor-bearing BALB/c mice treated with photodynamic therapy

Polish Journal of Pathology

Volumn 54, Issue 2, 2003, Pages 117-121

  Osiecka, Beata J ^a   Ziółkowski, Piotr ^a   Gamian, Elzbieta ^a   Lis Nawara, Anna ^a   Marszalik, Piotr ^a   White, Stephen G ^b   Bonnett, Raymond ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HALOGEN; HEMATOPORPHYRIN DERIVATIVE; HYDROXYGALLIUM PHTHALOCYANINE TETRASULFONIC ACID TETRASODIUM SALT; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FIBROSARCOMA; IN VIVO STUDY; IRRADIATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSPLANTATION; FIBROBLAST GROWTH FACTOR 2; FIBROSARCOMA; HEMATOPORPHYRIN DERIVATIVE; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY;

EID: 0141591530     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ali H, Langlois R, Wagner JR, Brasseur N, Paquette B, van Lier JE: Biological activities of phthalocyanines. X. Synthesis and analysis of sulfonated phthalocyanines. Photochem Photobiol 1988, 47, 713-717.
2. Bonnett R: Photodynamic therapy in historical perspective. Rev Contemp Pharmacother 1999, 10, 1-17.
3. Bonnett R: Chemical Aspects of Photodynamic Therapy. Gordon&Breach Science Publishers, Amsterdam 2000, Chap. 4.
4. Bonnett R, Nizhnik AN, White SG, Berenbaum MB: Porphyrin sensitisers in tumour phototherapy. Novel sensitisers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B:Biol 1990, 6, 29-37.
5. Breider MA, Lu X, Panjehpour M, Frazier DL: Cytokine modulation of endothelial cell sensitivity to photodynamic therapy. Lasers in Surgery and Medicine 1993, 13, 305-311.
6. Daliani D: Development of angiogenesis inhibition as therapy for prostate cancer. Oncology 2000, 14(Suppl 13), 21-23.
7. Edgren M, Lennemas B, Larsson A, Kalkner KM: Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res 2001, 21, 1423-1429.
8. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ: Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000, 60, 4066-4069.
9. Gabrilove JL: Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist 2001, 6(suppl 5), 4-7.
10. Hoekman K: SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001, 7(suppl 3), S134-138.
11. LaMuraglia GM, Adili F, Karp SJ, Statius van Eps RG, Watkins MT: Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: insights to its effect on the vascular wall. J Vasc Surg 1997, 26, 294-301.
12. Leunig A, Tauber S, Spaett R, Grevers G, Leunig M: Basic fibroblast growth factor in serum and urine of patients with head and neck cancer. Oncol Rep 1998, 5, 955-958.
13. Miguatti P, Tsuboi R, Robbins E, Rijkin DB: In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989, 108, 617-682.
14. Nash AD: Fibrosarcoma and fibromatosis. In: Soft Tissue Sarcomas. Histological Diagnosis. Biopsy Interpretation Series. Silverberg SG, ed. Raven Press, New York 1989, 9-20.
15. Ochsner M: Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B: Biol 1997, 39, 1-18.
16. Riedel F, Gotte K, Oulmi Y, Hormann K: Immunocytochemical localization of basic fibroblast growth factor in squamous cell carcinomas of the head and neck. Anticancer Res 2001, 21, 1873-1878.
17. Schuitmaker JJ, Baas P, van Leengoed HLLM, van der Meulen FW, Star WM, van Zandwijk N: Photodynamic therapy: a promising new modality for the treatment of cancer. J Photochem Photobiol B: Biol 1996, 34, 3-12.
18. Statius van Eps RG, Adili F, LaMuraglia GM: Photodynamic therapy inactivates cell-associated basic fibroblast growth factor: a silent way of vascular smooth muscle cell eradication. Cardiovasc Res 1997, 35, 334-340.
19. Westwood G, Dibling BC, Cuthbert-Heavens D, Burchill SA: Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene 2002, 21, 809-824.
20. Ziółkowski P, Symonowicz K, Milach J: In vivo interleukin-1-alpha induction following chlorin e6 photodynamic therapy in BALB/c mice. Proc. SPIE 1996, 2625, 426-433.
21. Ziółkowski P, Symonowicz K, Milach J, Zawirska B, Szkudlarek T: In vivo Tumor Necrosis Factor-alpha induction following chlorin e6-photodynamic therapy. Neoplasma 1997, 44, 192-196.
22. Ziółkowski P, Symonowicz K, Osiecka BJ, Rabczyński J, Gerber J: Photodynamic treatment of epithelial tissue derived from patients with endometrial cancer: a contribution to the role of laminin and epidermal growth factor receptor in photodynamic therapy. J Biomed Opt 1999, 4, 272-275.